Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Receivables: 2023-2025

Historic Change in Receivables for Fennec Pharmaceuticals (FENC) over the last 3 years, with Sep 2025 value amounting to $3.4 million.

  • Fennec Pharmaceuticals' Change in Receivables fell 18.10% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 23.61%. This contributed to the annual value of $7.9 million for FY2024, which is 8.31% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Change in Receivables stood at $3.4 million for Q3 2025, which was up 1,198.11% from $265,000 recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Change in Receivables high stood at $5.3 million for Q1 2025, and its period low was $138,000 during Q1 2023.
  • Its 3-year average for Change in Receivables is $2.2 million, with a median of $2.0 million in 2024.
  • Data for Fennec Pharmaceuticals' Change in Receivables shows a peak YoY increase of 957.97% (in 2024) and a maximum YoY decrease of 95.92% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Fennec Pharmaceuticals' Change in Receivables stood at $4.3 million in 2023, then slumped by 95.92% to $175,000 in 2024, then declined by 18.10% to $3.4 million in 2025.
  • Its Change in Receivables stands at $3.4 million for Q3 2025, versus $265,000 for Q2 2025 and $5.3 million for Q1 2025.